HF 2398 (LSB 5298HV (2) 84)

HOUSE FILE 2398

BY  COMMITTEE ON PUBLIC SAFETY

(SUCCESSOR TO HSB 609)

A BILL FOR

An Act  classifying certain substances as schedule I controlled substances, making penalties applicable, and including effective date provisions.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

    Section 1.  Section 124.201, subsection 4, Code 2011, is amended to read as follows:
   4.  If any new substance is designated as a controlled substance under federal law and notice of the designation is given to the board, the board shall similarly designate as controlled the new substance under this chapter after the expiration of thirty days from publication in the Federal Register of a final order designating a new substance as a controlled substance, unless within that thirty-day period the board objects to the new designation. In that case the board shall publish the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing the board shall announce its decision. Upon publication of objection to a new substance being designated as a controlled substance under this chapter by the board, control under this chapter is stayed until the board publishes its decision. If a substance is designated as controlled by the board under this paragraph
 
subsection the control shall be temporary and if within sixty days after the next regular session of the general assembly convenes it has not made the corresponding changes in this chapter, the temporary designation of control of the substance by the board shall be nullified.
    Sec. 2.  Section 124.204, subsection 4, paragraph ai, Code Supplement 2011, is amended by striking the paragraph and inserting in lieu thereof the following:
   ai.
  (1)  Salvia divinorum. 
   (2)  Salvinorin A.
   (3)  HU-210. [(6aR,10aR)-9-(hydroxymethyl)-6,6-

dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol)]. 
   (4)  HU-211(dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-

dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol). 
   (5)  Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
   (a)  The term “cannabimimetic agents” means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:
   (i)  2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.
   (ii)  3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent. 
   (iii)  3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.
   (iv)  1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.
   (v)  3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.
   (b)  Such terms include:
   (i)  CP 47, 497 and homologues 2-[(1R, 3S)-3- hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol). 
   (ii)  JWH-018 and AM678 1-Pentyl-3-(1-naphthoyl)indole. 
   (iii)  JWH-073 1-Butyl-3-(1-naphthoyl)indole. 

   (iv)  JWH-200 [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-

naphthalenyl-methanone.
   (v)  JWH-19 1-hexyl-3-(1-naphthoyl)indole.
   (vi)  JWH-81 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole. 
   (vii)  JWH-122 1-pentyl-3-(4-methyl-1-naphthoyl)indole.
   (viii)  JWH-250 1-pentyl-3-(2-methoxynaphthoyl)indole.
   (ix)  RCS-4 and SR-19 1-pentyl-3-[(4methoxy)-benzoyl]indole.
   (x)  RCS-8 and SR-18 1-cyclohexylethyl-3-

(-2-methoxyphenylacety)indole.
   (xi)  AM2201 1-(5-fluoropentyl)-3-(1-naphthoyl)indole.
   (xii)  JWH-203 1-pentyl-3-(2-chlorophenylacetyl)indole.
   (xiii)  JWH-398 1-pentyl-3-(4-chloro-1-naphthoyl)indole.
   (xiv)  AM694 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
   (xv)  Cannabicyclohexanol or CP–47,497 C8-homolog 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol.
    Sec. 3.  Section 124.204, subsection 6, Code Supplement 2011, is amended by adding the following new paragraph:
   NEW PARAGRAPH.  i.  Any substance, compound, mixture or preparation which contains any quantity of any synthetic cathinone that is not approved as a pharmaceutical, including but not limited to the following:
   (1)  Mephedrone, also known as 4-methylmethcathinone,(RS)-2-

methylamino-l-(4-methylphenyl) propan-1-one. 
   (2)  Methylene-dioxypyrovalerone(MDPV)[(1-(1,3- Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone]. 
   (3)  Methylone, also known as 3,4-methylenedioxymethcathinone.
   (4)  Naphthylpyrovalerone (naphyrone).
   (5)  4-fluoromethcathinone(flephedrone) or a positional isomer of 4-fluoromethcathinone. 
   (6)  4-methoxymethcathinone (methedrone;Bk-PMMA).
   (7)  Ethcathinone.
   (8)  3,4-methylenedioxyethcathinone(ethylone).
   (9)  Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone).

   (10)  N,N-dimethylcathinone(metamfepramone).
   (11)  Alpha-pyrrolidinopropiophenone (alpha-PPP).
   (12)  4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP).
   (13)  3,4-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP).
   (14)  Alpha-pyrrolidinovalerophenone (alpha-PVP).
   (15)  6,7-dihydro-5H-indeno(5,6-d)-1,3-dioxal-6 6-amine) (MDAI).
   (16)  3-fluoromethcathinone.
   (17)  4’-Methyl-α-pyrrolidinobutiophenone (MPBP).
   (18)  2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E).
   (19)  2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D).
   (20)  2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C).
   (21)  2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I).
   (22)  2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2).
   (23)  2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4).
   (24)  2-(2,5-Dimethoxyphenyl)ethanamine (2C–H).
   (25)  2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C–N).
   (26)  2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P).
    Sec. 4.  Section 124.401, subsection 1, paragraph d, Code Supplement 2011, is amended to read as follows:
   d.  Violation of this subsection, with respect to any other controlled substances, counterfeit substances, or simulated controlled substances classified in section 124.204, subsection 4, paragraph “ai”,
 
section 124.204, subsection 6, paragraph “i”, or classified in schedule IV or V is an aggravated misdemeanor. However, violation of this subsection involving fifty kilograms or less of marijuana or involving flunitrazepam is a class “D” felony.
    Sec. 5.  EFFECTIVE UPON ENACTMENT.  This Act, being deemed of immediate importance, takes effect upon enactment.
EXPLANATION
   This bill classifies certain substances as schedule I controlled substances, and makes penalties applicable.
   The bill adds numerous synthetic cannabinoids, also known as “K2”, to the list of schedule I controlled substances in Code section 124.204(4)(ai). 
   The bill adds numerous substances containing any quantity of any synthetic cathinone that are not approved pharmaceuticals to the list of schedule I controlled substances in Code section 124.204(6). 
   A schedule I controlled substance is considered to have a high potential for abuse and no medical purpose in treatment in the United States. 
   Under the bill, it is an aggravated misdemeanor pursuant to Code section 124.401(1)(d) for any unauthorized person to manufacture, deliver, or possess with the intent to manufacture or deliver a synthetic cannabinoid classified as a schedule I controlled substance in Code section 124.204(4)(ai) including its counterfeit or simulated form, or to act with, enter into a common scheme or design with, or conspire with one or more persons to manufacture, deliver, or possess with the intent to manufacture or deliver such a schedule I controlled substance. 
   It is also an aggravated misdemeanor pursuant to Code section 124.401(1)(d) under the bill for any unauthorized person to manufacture, deliver, or possess with the intent to manufacture or deliver a synthetic cathinone classified as a schedule I controlled substance in Code section 124.204(6)(i) including its counterfeit or simulated form, or to act with, enter into a common scheme or design with, or conspire with one or more persons to manufacture, deliver, or possess with the intent to manufacture or deliver such a schedule I controlled substance.
   It is also a serious misdemeanor for a first offense violation of Code section 124.401(5) for any unauthorized person to possess a controlled substance classified as a schedule I controlled substance.
   An aggravated misdemeanor is punishable by confinement for no more than two years and a fine of at least $625 but not more than $6,250. A serious misdemeanor is punishable by confinement for no more than one year and a fine of at least $315 but not more than $1,875.
   The bill takes effect upon enactment.